Clinical trial data shows diarrhea rates of 19-23% across doses, with nausea remaining the predominant side effect at 24-31%
First, it involved a patient who already had neuropathy, raising the question of whether pre-existing nerve damage creates vulnerability to GLP-1-associated allodynia
Previous data demonstrated that activation of GLP-1R could alleviate neuropathic pain, cancer pain and diabetic neuropathy [20]
A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide
(which operates as Hims and Hers) Location: San Francisco, CaliforniaStore Websites: and Letter Date: September 9, 2025FDA Department issuing Warning: Center for Drug Evaluation and Research (CDER)Types of Products Sold: Prescribes and sells compounded semaglutide, tirzepatide and other compounded productsType of Warning: Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the InternetFDA Warning: The website makes false claims about compounded drug products, including: Same active ingredient as Ozempic and Wegovy and Clinically proven ingredients. The claims imply that the products are the same as an FDA-approved product when they are not
Participants were generally prescribed GLP-1RAs for non-alcohol-related indications and were not specifically recruited for AUD treatment
